How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Stroke Testing Biomarkers Market
- By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Metabolite Biomarkers, Inflammatory Biomarkers, Coagulation Biomarkers
- By Application: Early Diagnosis, Prognosis Assessment, Therapeutic Monitoring, Risk Stratification, Recurrence Prediction
- By Sample Type: Blood Plasma, Serum, Cerebrospinal Fluid, Urine, Saliva
- By End User: Hospitals, Diagnostic Laboratories, Research Institutes, Point-of-Care Testing Centers
- By Technology Platform: Immunoassays, Mass Spectrometry, Polymerase Chain Reaction (PCR), Microarray Analysis, Next-Generation Sequencing
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Protein Biomarkers leads By Biomarker Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 310 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.184 →
- 12 Company Profiles 18 players: SWOT & benchmarking p.192 →
Full report · locked preview
Everything inside the Stroke Testing Biomarkers Market report
A complete, evidence-based study - 12 chapters and 130 sections covering market size, segmentation across 5 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Biomarker Type 5
Application 5
Sample Type 5
End User 4
Technology Platform 5
Companies profiled
Abbott Laboratories
Siemens Healthineers
Roche Diagnostics
BioMérieux
Quanterix Corporation
SomaLogic Inc.
Biosite
Inc. (now part of Alere
Abbott)
Sekisui Diagnostics
Ortho Clinical Diagnostics (part of Ortho Clinical Diagnostics Holdings)
DiaSorin S.p.A.
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →BioMérieux
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Quanterix Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →SomaLogic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Biosite
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Inc. (now part of Alere
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Abbott)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sekisui Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Ortho Clinical Diagnostics (part of Ortho Clinical Diagnostics Holdings)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →DiaSorin S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Fujirebio Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Myriad Genetics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →Cytokinetics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Nanosphere
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc. (acquired by Luminex Corporation)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →HemoShear Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,588M by 2033 · 8.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Protein Biomarkers51.4
- Genetic Biomarkers9.5
- Metabolite Biomarkers14.0
- Inflammatory Biomarkers15.6
- Coagulation Biomarkers9.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$456.1M → $795.2M · 7.2%
Europe$317.9M → $622.8M · 8.8%
Asia Pacific$290.2M → $513.0M · 7.4%
Latin America$179.7M → $344.0M · 8.5%
Middle East and Africa$138.2M → $242.2M · 7.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.112026
8.132027
8.132028
8.152029
8.162030
8.182031
8.172032
8.192033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories14.0
- Siemens Healthineers23.2
- Roche Diagnostics7.6
- BioMérieux13.5
- Quanterix Corporation4.8
- SomaLogic Inc.8.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Biomarker Type10.3%
Application14.6%
Sample Type22.8%
End User28.0%
Technology Platform24.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.6
- Europe24.7
- Asia Pacific20.4
- Latin America13.7
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 89 | 89 | 78 | 94 | 93 | 98 | 90 |
| Siemens Healthineers | 92 | 72 | 80 | 86 | 79 | 75 | 81 |
| Roche Diagnostics | 70 | 68 | 69 | 80 | 75 | 83 | 74 |
| BioMérieux | 68 | 73 | 57 | 63 | 68 | 77 | 68 |
| Quanterix Corporation | 57 | 66 | 66 | 64 | 70 | 70 | 66 |
| SomaLogic Inc. | 50 | 57 | 64 | 48 | 51 | 52 | 54 |
| Biosite | 53 | 53 | 55 | 50 | 62 | 66 | 57 |
| Inc. (now part of Alere | 48 | 42 | 42 | 53 | 48 | 51 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Siemens Healthineers
- Roche Diagnostics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Siemens Healthineers | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Roche Diagnostics | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| BioMérieux | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| Quanterix Corporation | ◐ | − | − | − | − | ◐ |
| SomaLogic Inc. | ◐ | − | ◐ | − | − | − |
| Biosite | − | − | ◐ | ◐ | − | ◐ |
| Inc. (now part of Alere | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories90
2Siemens Healthineers81
3Roche Diagnostics74
4BioMérieux68
5Quanterix Corporation66
6Biosite57
7SomaLogic Inc.54
8Inc. (now part of Alere47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesSiemens Healthineers
Challenger2
Strong scale, closing on the leaders.
Roche DiagnosticsBioMérieux
Contender2
Focused players with pockets of strength.
Quanterix CorporationBiosite
Niche2
Specialists in a single segment or region.
SomaLogic Inc.Inc. (now part of Alere
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Biomarker Type in North America, then scale across Stroke Testing Biomarkers Market — a $375M beachhead inside a $6.66B market.
Beachhead (SOM)$375Mobtainable near-term
Serviceable (SAM)$2.29Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Protein Biomarkers
Best fit — highest urgency & budget in Biomarker Type.
Economic buyer78 fit
Genetic Biomarkers
Strong fit — clear ROI and a fast path to value.
End user65 fit
Metabolite Biomarkers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Biomarker Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sample Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel28%
Digital / self-serve21%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Biomarker Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Stroke Testing Biomarkers Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified20%
Evaluation12%
Closed-won6%
$17.0KCAC
$59KLTV
3.5:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Stroke Testing Biomarkers Market is a resilient opportunity — $838M by 2033, compounding at 5.1%.
TAM · 2025$563Mtoday
TAM · 2033$838Mforecast
CAGR5.1%2027–2033
Cumulative$6.23Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$838MTotal addressable market
SAM$306MServiceable available market
SOM$58MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.1% CAGR
Demand compounds through 2033, outpacing GDP across Biomarker Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Biomarker Type moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$838MLarge & growingTAM by 2033 at 5.1% CAGR
$306MServiceable nowreachable with today’s model
$58MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$654MBear3.3% CAGR
$838MBase5.1% CAGR
$1.07BBull6.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Stroke Testing Biomarkers Market — a $1.09B market by 2033. Plan: grow share from 8.4% to 17.1%.
Market size · 2033$1.09Btotal addressable
Market CAGR8.1%2027–2033
Target share17.1%from 8.4% today
Revenue ambition$186Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 17.1% | On track |
| Revenue | $88M | $186M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 32.8% | 39.6% | On track |
| Customer retention | 91.5% | 95.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Biomarker Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Biomarker Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $20M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Biomarker Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Stroke Testing Biomarkers Market conversation — a $968M market you can size, segment and defend in minutes.
Market size · 2033$968Mtotal opportunity
Growth10.1%CAGR to 2033
Addressable buyers1,451+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Biomarker Type
Goal Grow share in Biomarker Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 2 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
Abbott LaboratoriesSiemens HealthineersRoche DiagnosticsBioMérieuxQuanterix CorporationSomaLogic Inc.BiositeInc. (now part of Alere+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Stroke Testing Biomarkers Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Stroke Testing Biomarkers Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Stroke Telemedicine Services Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportStroke-physiological Saline Solution Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportStroke Management Device Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportStroke Diagnostics Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportStrip Warmer Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportStrip Test Handler Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportStrip Readers Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportStretch Mark Treatment Product Market
Market size, share, segmentation and regional forecast.
$569M market · 2025 base year
View reportStretch Marks Removal Products Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportStretch Marks Lightening Treatment Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportStretch Mark Removal Products Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportStretch Mark Removal Machines Market
Market size, share, segmentation and regional forecast.
$510M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.